| Previous Close | 231.94 |
| Open | 231.33 |
| Bid | 0.00 x 900 |
| Ask | 231.62 x 900 |
| Day's Range | 229.35 - 231.74 |
| 52 Week Range | 128.52 - 237.47 |
| Volume | 1,192,826 |
| Avg. Volume | 963,591 |
| Market Cap | 44.316B |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | 110.10 |
| EPS (TTM) | 2.10 |
| Earnings Date | Jul. 20, 2021 - Jul. 26, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 256.32 |
- Zacks
3 Reasons Why Growth Investors Shouldn't Overlook IQVIA (IQV)
IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.
- Business Wire
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.
- Business Wire
Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study
Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the durability of immunity and the continued emergence of viral variants make an endemic virus the most likely outcome.
